| Literature DB >> 26167498 |
Hemang K Pandya1, Lisa J Faia2, Joshua Robinson2, Kimberly A Drenser3.
Abstract
Purpose. To report anatomic outcomes after early and confluent laser photocoagulation of the entire avascular retina, including areas in close proximity to the fovea, in patients with APROP. We aspire to demonstrate fundoscopic evidence of transverse growth and macular development following laser treatment in APROP. Methods. Retrospective review of 6 eyes with APROP that underwent confluent laser photocoagulation of the entire avascular retina. Photographic fundoscopic imaging was performed using the RetCam to compare outcomes after treatment. Results. Mean birth weight and gestational age were 704.8 g and 24.33 weeks, respectively. There were 2 females and 1 male. The average time to laser was 9.3 weeks after birth, with the mean postmenstrual age of 34 weeks. Two eyes had zone 1 and 4 eyes had posterior zone 2 disease. Three eyes developed 4A detachments, which were successfully treated. All 6 eyes experienced transverse growth, with expansion of the posterior pole and anterior displacement of the laser treatment. Conclusion. Confluent photocoagulation of the entire avascular retina, regardless of foveal proximity, should be the mainstay for treating APROP. Examination should be conducted within 5-10 days to examine areas previously hidden by neovascularization to ensure prudent therapy. Macular development involves both transverse and anterior-posterior growth.Entities:
Mesh:
Year: 2015 PMID: 26167498 PMCID: PMC4488519 DOI: 10.1155/2015/808639
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Patient demographics and clinical information.
| Patient | Gender | Race | Gestational age (weeks) | Birth weight (grams) | Comorbidities | Initial ROP staging | Initial Plus disease | Initial laser (weeks) |
|---|---|---|---|---|---|---|---|---|
| 1 | Male | African- | 23 6/7 | 760 | Hydrocephalus s/p ventriculoparietal shunt, bowel perforation | OD: stage 3, zone 1 | OD: 2-3+ | PRP OU @ 33 5/7 |
|
| ||||||||
| 2 | Female | Caucasian | 23 4/7 | 525 | Pulmonary hypertension, conductive hearing loss | OD: stage 2, zone 2 | OD: 2-3+ | PRP OU @ 36 |
|
| ||||||||
| 3 | Female | Caucasian | 25 4/7 | 829 | Pulmonary hypertension | OD: stage 3, zone 1 | OD: 2-3+ | PRP OU @ 33 5/7 |
Figure 1
Figure 2
Figure 3